| Document Date: 2014-11-06 23:50:12
Open Document File Size: 2,68 MBShare Result on Facebook
Company Roche Diagnostics Australia Pty Ltd / GlaxoSmithKline Australia / / Country Australia / / Event FDA Phase / / Facility The laboratory / / IndustryTerm healthcare resources / draft decision analytic protocol / decision analytic protocol / nucleotide solution / / MedicalCondition cancer / disease / IV disease / congenital disorders / metastasis / skin cancer / IV melanoma / tumour / melanomas / infectious / melanoma / cutaneous melanoma / infectious disease / tumours / metastatic melanoma / / MedicalTreatment bypass / / Organization Therapeutic Goods Administration / Australian government / Department of Health / Medical Services Advisory Committee / Medicare / / Position Commonwealth Minister / Governor / Health Minister / / Product dacarbazine / V600 / / Technology radiation / electrophoresis / Final Decision Analytical Protocol / decision analytic protocol / draft decision analytic protocol / gene expression / / URL http /
SocialTag |
1207: Final Decision Analytical Protocol (DAP) to guide the assessment of BRAF V600 mutation